NCT01402414 is a NA clinical trial of NB-UVB in Atopic Dermatitis, sponsored by Ruhr University of Bochum.

Who is sponsoring NCT01402414?

NCT01402414 is sponsored by Ruhr University of Bochum.

What drugs are being tested in NCT01402414?

Interventions in NCT01402414: NB-UVB, Bath-PUVA, NB-UVB plus salt water baths.

What condition does NCT01402414 study?

NCT01402414 studies Atopic Dermatitis.

Is NCT01402414 still recruiting?

NCT01402414 is currently terminated. Last updated 20 February 2014.

Last reviewed 2014-02-20 · How we verify

NCT01402414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Comparing the Effectiveness of Narrow-band UVB vs. Bath-PUVA and Narrow-band UVB + Salt Water Baths in Atopic Dermatitis

Terminated NA Last updated 20 February 2014

What this trial tests

NA trial testing NB-UVB in Atopic Dermatitis in 10 participants. Terminated before completion.

Timeline

1 April 2011

Primary endpoint
1 February 2014

1 February 2014

Quick facts

Lead sponsor	Ruhr University of Bochum
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	1 April 2011
Primary completion	1 February 2014
Estimated completion	1 February 2014
Sites	1 location across Germany

Drugs / interventions tested

NB-UVB — full drug profile →
Bath-PUVA
NB-UVB plus salt water baths

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Ruhr University of Bochum

Who can join

18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical improvement after treatments using a validated SASSAD index
Time frame: Evaluation at baseline and after 4-week treatment, 3 months follow-up
Clinical improvement after treatments using a validated SASSAD index

Sponsor's own description

In this controlled crossover study we aim to compare the efficacy of narrow-band UVB (NB-UVB) with bath-PUVA and NB-UVB plus salt water baths in atopic dermatitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phototherapy for atopic eczema.
Musters AH, Mashayekhi S, Harvey J, Axon E, et al · · 2021 · cited 22× · PMID 34709669 · DOI 10.1002/14651858.cd013870.pub2

Verify or expand the search:

Other trials of NB-UVB

Trials testing the same drug.

NCT06593197 — Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients · Phase 4 · enrolling by invitation
NCT06712238 — Evaluation The Effect of NB-UVB and Methotrexate on The Level of Serum Gelsolin in Psoriatic Patients · NA · recruiting
NCT04811326 — Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation · Phase 4 · unknown
NCT05647187 — Effect Narrow-Band UVB Radiations · NA · completed
NCT04071106 — Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial · Phase 2, PHASE3 · unknown

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Ruhr University of Bochum trials

Trials by the same sponsor.

NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
NCT06255821 — The Effect of Time on Generalization of Exposure-based Benefit · NA · completed
NCT05824884 — Self-efficacy Enhancement in a Virtual Reality Training for Fear of Heights · NA · recruiting
NCT05798078 — The Relationship Between Social Anxiety and Anxious Thinking Styles · NA · completed
NCT05780203 — CBM in the Context of Exposure for Acrophobia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01402414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruhr University of Bochum
Last refreshed: 20 February 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01402414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing